CAT Proposed NASDAQ Listing

Cambridge Antibody Tech Group PLC
4 April 2001


For Further Information Contact:

Cambridge Antibody Technology        
Tel: [phone]
David Chiswell, CEO
John Aston, Finance Director       
Rowena Gardner, Head of Corporate Communications       

HCC De Facto (Europe)
Tel: [phone]
Adam Michael
David Speechly
                                                                              
BMC Communications/The Trout Group (USA)
Tel: [phone]
Brad Miles, ext 17 (media)
Brandon Lewis, ext.15 (investors)


PROPOSED NASDAQ LISTING: 
CAT MAKES PUBLIC FILING WITH SEC

Melbourn, UK Cambridge Antibody Technology (LSE : CAT) announces that it has
now made a public filing with the SEC in preparation for its proposed listing
of ADRs on the NASDAQ market, as previously announced.  This filing follows an
extensive period of consultation with the SEC.  The filing of a registration
statement does not guarantee that CAT's ADRs will be listed at any time or at
all.



Notes to Editors:

Cambridge Antibody Technology (LSE: CAT)
CAT is a UK biotechnology company using its proprietary technologies in human
monoclonal antibodies for drug discovery and drug development.  Based in
Melbourn, 10 miles south of Cambridge, England, CAT currently employs around
210 people.  
CAT's ordinary shares are listed on the London Stock Exchange.  CAT raised
£41m in its IPO in March 1997 and £93m (£89.4m net of expenses) in a secondary
offering in March 2000. 
CAT has an advanced platform technology for rapidly isolating human monoclonal
antibodies, primarily using phage display technology. CAT's library currently
incorporates around 100 billion distinct antibodies. This library forms the
basis for the company's strategy to develop a portfolio of clinical
development programmes and for discovering new drug leads using functional
genomics. Four human therapeutic antibodies developed by CAT are at various
stages of clinical trials. 
CAT works in partnership with other companies at all stages of the drug
discovery and development process. CAT's collaborations, past and present,
include: AstraZeneca, Knoll AG, Eli Lilly, Genentech,  Genetics Institute,
Genzyme,  Human Genome Sciences,   Immunex,  Oxford GlycoSciences,  Pharmacia,
Pfizer, Wyeth-Ayerst and Zyomyx.